HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-Term Efficacy and Safety of Partial Splenic Embolization in Hepatocellular Carcinoma Patients with Thrombocytopenia Who Underwent Transarterial Chemoembolization.

AbstractBACKGROUND:
Performing transarterial chemoembolization (TACE) is difficult with the occurrence of thrombocytopenia in cirrhotic patients with hepatocellular carcinoma (HCC). We aimed to evaluate the long-term efficacy and safety of partial splenic embolization (PSE) combined with TACE in patients with HCC with severe thrombocytopenia related to splenomegaly.
METHODS:
We conducted a case-control study consisting of 18 HCC patients with severe thrombocytopenia (< 50 × 10⁹/L) who underwent PSE concurrently with TACE (PSE group) and 72 controls who underwent TACE alone (non-PSE group).
RESULTS:
Mean platelet counts at 1 month and 1, 3, and 5 years after concurrent PSE and TACE significantly increased compared with baseline (all P < 0.05), whereas the platelet count did not significantly increase after TACE alone. In addition, the platelet count at several time points after treatment in the PSE group was significantly higher than that in the non-PSE group, although the baseline platelet count in the PSE group was significantly lower than that in the non-PSE group. The platelet increase after PSE significantly reduced the need for platelet transfusions (P = 0.040) and enabled the subsequent TACE procedures in time (P = 0.046). The leukocyte counts and hemoglobin concentrations after concurrent PSE and TACE were also significantly increased, without deterioration of Child-Turcotte-Pugh score and unexpected side effects.
CONCLUSION:
PSE combined with TACE is effective in inducing and maintaining long-term thrombocytopenia improvement which reduces the need for the platelet transfusion and helps to perform initial and serial TACE, and is well-tolerated in patients with HCC and thrombocytopenia. PSE may be a promising treatment option for HCC patients with severe thrombocytopenia associated with splenomegaly who will undergo TACE.
AuthorsNam Hee Kim, Hong Joo Kim, Yong Kyun Cho, Hyun Pyo Hong, Byung Ik Kim
JournalJournal of Korean medical science (J Korean Med Sci) Vol. 34 Issue 30 Pg. e208 (Aug 05 2019) ISSN: 1598-6357 [Electronic] Korea (South)
PMID31373186 (Publication Type: Journal Article)
Copyright© 2019 The Korean Academy of Medical Sciences.
Chemical References
  • Hemoglobins
Topics
  • Adult
  • Aged
  • Carcinoma, Hepatocellular (complications, mortality, therapy)
  • Case-Control Studies
  • Chemoembolization, Therapeutic
  • Embolization, Therapeutic (methods)
  • Female
  • Hemoglobins (analysis)
  • Humans
  • Leukocyte Count
  • Liver Neoplasms (complications, mortality, therapy)
  • Male
  • Middle Aged
  • Platelet Count
  • Retrospective Studies
  • Splenic Artery (surgery)
  • Splenomegaly (complications, diagnosis)
  • Survival Rate
  • Thrombocytopenia (complications, diagnosis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: